Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer

por Cabanos, Heidie Frisco, Hata, Aaron N.
Publicado 2021

Stitchr: stitching coding TCR nucleotide sequences from V/J/CDR3 information

por Heather, James M, Spindler, Matthew J, Alonso, Marta Herrero, Shui, Yifang Ivana, Millar, David G, Johnson, David S, Cobbold, Mark, Hata, Aaron N
Publicado 2022

Alginate-based 3D cancer cell culture for therapeutic response modeling

por Davoudi, Farideh, Ghorbanpoor, Samar, Yoda, Satoshi, Pan, Xiao, Crowther, Giovanna Stein, Yin, Xunqin, Murchie, Ellen, Hata, Aaron N., Willers, Henning, Benes, Cyril H.
Publicado 2021

Correction to: MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister state

por Zhang, Wen Cai, Skiados, Nicholas, Aftab, Fareesa, Moreno, Cerena, Silva, Luis, Corbilla, Paul Joshua Anthony, Asara, John M., Hata, Aaron N., Slack, Frank J.
Publicado 2022

MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister state

por Zhang, Wen Cai, Skiados, Nicholas, Aftab, Fareesa, Moreno, Cerena, Silva, Luis, Corbilla, Paul Joshua Anthony, Asara, John M., Hata, Aaron N., Slack, Frank J.
Publicado 2022

Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction

por Vaccaro, Kyle, Allen, Juliet, Whitfield, Troy W., Maoz, Asaf, Reeves, Sarah, Velarde, José, Yang, Dian, Phan, Nicole, Bell, George W., Hata, Aaron N., Weiskopf, Kipp
Publicado 2023

Fatty acids and cancer-amplified ZDHHC19 promote STAT3 activation through S-Palmitoylation

por Niu, Jixiao, Sun, Yang, Chen, Baoen, Zheng, Baohui, Jarugumilli, Gopala K., Walker, Sarah R., Hata, Aaron N., Mino-Kenudson, Mari, Frank, David A., Wu, Xu
Publicado 2019

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

por Marcar, Lynnette, Bardhan, Kankana, Gheorghiu, Liliana, Dinkelborg, Patrick, Pfäffle, Heike, Liu, Qi, Wang, Meng, Piotrowska, Zofia, Sequist, Lecia V., Borgmann, Kerstin, Settleman, Jeffrey E., Engelman, Jeffrey A., Hata, Aaron N., Willers, Henning
Publicado 2019

Targeting the DNA replication stress phenotype of KRAS mutant cancer cells

por Al Zubaidi, Tara, Gehrisch, O. H. Fiete, Genois, Marie-Michelle, Liu, Qi, Lu, Shan, Kung, Jong, Xie, Yunhe, Schuemann, Jan, Lu, Hsiao-Ming, Hata, Aaron N., Zou, Lee, Borgmann, Kerstin, Willers, Henning
Publicado 2021

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers

por Hata, Aaron N, Rowley, Steve, Archibald, Hannah L, Gomez-Caraballo, Maria, Siddiqui, Faria M, Ji, Fei, Jung, Joonil, Light, Madelyn, Lee, Joon Sang, Debussche, Laurent, Sidhu, Sukhvinder, Sadreyev, Ruslan I, Watters, James, Engelman, Jeffrey A
Publicado 2017

Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer

por Nardi, Francesca, Perurena, Naiara, Schade, Amy E., Li, Ze-Hua, Ngo, Kenneth, Ivanova, Elena V., Saldanha, Aisha, Li, Chendi, Gokhale, Prafulla C., Hata, Aaron N., Barbie, David A., Paweletz, Cloud P., Jänne, Pasi A., Cichowski, Karen
Publicado 2023

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics

por Fraser, Cameron S., Spetz, Johan K. E., Qin, Xingping, Presser, Adam, Choiniere, Jonathan, Li, Chendi, Yu, Stacey, Blevins, Frances, Hata, Aaron N., Miller, Jeffrey W., Bradshaw, Gary A., Kalocsay, Marian, Sanchorawala, Vaishali, Sarosiek, Shayna, Sarosiek, Kristopher A.
Publicado 2022

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

por Poels, Kamrine E., Schoenfeld, Adam J., Makhnin, Alex, Tobi, Yosef, Wang, Yuli, Frisco-Cabanos, Heidie, Chakrabarti, Shaon, Shi, Manli, Napoli, Chelsi, McDonald, Thomas O., Tan, Weiwei, Hata, Aaron, Weinrich, Scott L., Yu, Helena A., Michor, Franziska
Publicado 2021

Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

por Poels, Kamrine E., Schoenfeld, Adam J., Makhnin, Alex, Tobi, Yosef, Wang, Yuli, Frisco-Cabanos, Heidie, Chakrabarti, Shaon, Shi, Manli, Napoli, Chelsi, McDonald, Thomas O., Tan, Weiwei, Hata, Aaron, Weinrich, Scott L., Yu, Helena A., Michor, Franziska
Publicado 2022

Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells

por Ali, Moiez, Lu, Min, Ang, Hazel Xiaohui, Soderquist, Ryan S., Eyler, Christine E., Hutchinson, Haley M., Glass, Carolyn, Bassil, Christopher F., Lopez, Omar M., Kerr, D. Lucas, Falcon, Christina J., Yu, Helena A., Hata, Aaron N., Blakely, Collin M., McCoach, Caroline E., Bivona, Trever G., Wood, Kris C.
Publicado 2022

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

por Katayama, Ryohei, Gong, Bo, Togashi, Noriko, Miyamoto, Masaya, Kiga, Masaki, Iwasaki, Shiho, Kamai, Yasuki, Tominaga, Yuichi, Takeda, Yasuyuki, Kagoshima, Yoshiko, Shimizu, Yuki, Seto, Yosuke, Oh-hara, Tomoko, Koike, Sumie, Nakao, Naoki, Hanzawa, Hiroyuki, Watanabe, Kengo, Yoda, Satoshi, Yanagitani, Noriko, Hata, Aaron N., Shaw, Alice T., Nishio, Makoto, Fujita, Naoya, Isoyama, Takeshi
Publicado 2019

Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition

por Lin, Jessica J., Langenbucher, Adam, Gupta, Pranav, Yoda, Satoshi, Fetter, Isobel J., Rooney, Marguerite, Do, Andrew, Kem, Marina, Chang, Kylie Prutisto, Oh, Audris Y., Chin, Emily, Juric, Dejan, Corcoran, Ryan B., Dagogo-Jack, Ibiayi, Gainor, Justin F., Stone, James R., Lennerz, Jochen K., Lawrence, Michael S., Hata, Aaron N., Mino-Kenudson, Mari, Shaw, Alice T.
Publicado 2020

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

por Raoof, Sana, Mulford, Iain J., Frisco-Cabanos, Heidie, Nangia, Varuna, Timonina, Daria, Labrot, Emma, Hafeez, Nafeeza, Bilton, Samantha J., Drier, Yotam, Ji, Fei, Greenberg, Max, Williams, August, Kattermann, Krystina, Damon, Leah, Sovath, Sosathya, Rakiec, Daniel P., Korn, Joshua M., Ruddy, David A., Benes, Cyril H., Hammerman, Peter S., Piotrowska, Zofia, Sequist, Lecia V., Niederst, Matthew J., Barretina, Jordi, Engelman, Jeffrey A., Hata, Aaron N.
Publicado 2019

NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations

por Drilon, Alexander, Horan, Joshua C., Tangpeerachaikul, Anupong, Besse, Benjamin, Ou, Sai-Hong Ignatius, Gadgeel, Shirish M., Camidge, D. Ross, van der Wekken, Anthonie J., Nguyen-Phuong, Linh, Acker, Adam, Keddy, Clare, Nicholson, Katelyn S., Yoda, Satoshi, Mente, Scot, Sun, Yuting, Soglia, John R., Kohl, Nancy E., Porter, James R., Shair, Matthew D., Zhu, Viola, Davare, Monika A., Hata, Aaron N., Pelish, Henry E., Lin, Jessica J.
Publicado 2023

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

por Hata, Aaron N, Niederst, Matthew J, Archibald, Hannah L, Gomez-Caraballo, Maria, Siddiqui, Faria M, Mulvey, Hillary E, Maruvka, Yosef E, Ji, Fei, Bhang, Hyo-eun C, Radhakrishna, Viveksagar Krishnamurthy, Siravegna, Giulia, Hu, Haichuan, Raoof, Sana, Lockerman, Elizabeth, Kalsy, Anuj, Lee, Dana, Keating, Celina L, Ruddy, David A, Damon, Leah J, Crystal, Adam S, Costa, Carlotta, Piotrowska, Zofia, Bardelli, Alberto, Iafrate, Anthony J, Sadreyev, Ruslan I, Stegmeier, Frank, Getz, Gad, Sequist, Lecia V, Faber, Anthony C, Engelman, Jeffrey A
Publicado 2016